Last reviewed · How we verify
Ritonavir Tablet 100mg
At a glance
| Generic name | Ritonavir Tablet 100mg |
|---|---|
| Sponsor | First Affiliated Hospital of Zhejiang University |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Blood sodium decreased
- Blood cholesterol increased
- Diarrhoea
- Nausea
- Low density lipoprotein increased
- Headache
- Blood bicarbonate decreased
- Aspartate aminotransferase increased
- Blood phosphorus decreased
- Blood alkaline phosphatase increased
- Cough
- Neutrophil count decreased
Key clinical trials
- RECOVER-VITAL: Platform Protocol, Appendix to Measure the Effects of Paxlovid on Long COVID Symptoms (PHASE2)
- Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV) (PHASE2)
- Lopinavir/Ritonavir in PLWH With High-Grade AIN (PHASE1)
- AGILE (Early Phase Platform Trial for COVID-19) (PHASE1, PHASE2)
- RECOVER-VITAL: Platform Protocol to Measure the Effects of Antiviral Therapies on Long COVID Symptoms (PHASE2)
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- PAxlovid loNg cOvid-19 pRevention triAl With recruitMent In the Community in Norway (PHASE3)
- Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ritonavir Tablet 100mg CI brief — competitive landscape report
- Ritonavir Tablet 100mg updates RSS · CI watch RSS
- First Affiliated Hospital of Zhejiang University portfolio CI